CompaniesGD Searle

GD Searle

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

3

As Collaborator

1

Total Enrollment

378

By Phase

PHASE1: 1PHASE2: 3

By Status

COMPLETED: 4
Clinical Trials Pipeline

No trials with date information available

Recent Trials

NCT00000692Lead Sponsor
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
PHASE1Completed
48 participants
NCT00001993Lead Sponsor
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
PHASE2Completed
120 participants
NCT00002079Lead Sponsor
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
PHASE2Completed
NCT00000791Collaborator
A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV
PHASE2Completed
210 participants
Related Companies
Monsanto 1985
acquired
GD Searle | Biotech Hunter | Biotech Hunter